Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 3, 2000, Pages 231-238

  Vincent, Patrick W ^a   Bridges, Alex J ^a   Dykes, Donald J ^b   Fry, David W ^a   Leopold, Wilber R ^a   Patmore, Sandra J ^a   Roberts, Billy J ^a   Rose, Steven ^a   Sherwood, Veronika ^a   Zhou, Hairong ^a   Elliott, William L ^a  

^a PFIZER INC   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Epidermal growth factor receptor; Human tumor xenograft; In vivo; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PD 0169414; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0033968986     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050034     Document Type: Article

References (30)

1. 1. Aaronson SA (1991) Growth factors and cancer. Science 254: 1146-1152
2. 2. Aderem AA (1993) How cytokines signal messages in cells. J Infect Dis 167 [Suppl 1]: S2-7
3. 3. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelshon (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xeno-grafts. Cancer Res 58: 2825-2831
4. 4. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HDH, Fry DW, Kraker AJ, Denny WA (1996) Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromo-anilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem 39: 267-276
5. 5. Cadena DL, Gill GN (1992) Receptor tyrosine kinases. FASEB J 6: 2332-2337
6. 6. Carpenter G (1987) Receptors for EGF and other polypeptide mitogens. Annu Rev Biochem 56: 881-914
7. 7. Cohen S, Carpenter G, King L (1980) Epidermal growth factor-receptor-protein kinase interactions. J Biol Chem 258: 4834-4842
8. 8. Decker SJ (1984) Aspects of the metabolism of the epidermal growth factor receptor in A431 human epidermoid carcinoma cells. Mol Cell Biol 4: 571-575
9. Ha oncogene but does not block in vitro keratinocyte responses to oncogenic ras. Cancer Res 57: 3180-3188
10. 10. Elliott WL, Howard CT, Dykes DJ, Leopold WR (1989) Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res 49: 5586-5590
11. 11. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265: 1093-1095
12. 12. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95: 12022-12027
13. 13. Fry DW, Nelson JM, Slintak V, Keller PR, Loo J, Greis K, Trump-Kallmeyer S, Denny WA, Smaill JB, Showalter HDH, Bridges AJ, Zhou H, McNamara DJ, Dobrusin EM (1998) Specific, irreversible inhibitors of the epidermal growth factor receptor (EGFR) family of tyrosine kinases (meeting abstract). In: Proceedings of the Annual Meeting of the Association of Cancer Research, vol 39. Cadmus Journal Services, Linthicum, p 560
14. 14. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J (1984) Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine kinase activity. J Biol Chem 259: 7755-7760
15. 15. Gullick WJ (1991) Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87-98
16. 16. Hartmut J, Downing SG, Wellstein A, Czubayko F (1997) HER-2/neu is rate-limiting for ovarian cancer growth. J Biol Chem 272: 29482-29486
17. 17. Hynes NE (1993) Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Cancer Biol 4: 19-26
18. 18. Jones J, Lagasse LD, Karlan BY (1994) Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. Gynecol Oncol 55: 421-426
19. 19. Kaladhar BR, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK (1992) Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res 52: 3636-3641
20. 20. Leopold WR, Nelson JM, Plowman J, Jackson RC (1985) Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res 45: 5532-5539
21. 21. Lyall RM, Zilberstein A, Gazit A, Gilon C, Levitzki A, Schlessinger J (1989) Tryphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-simulated cell proliferation. J Biol Chem 264: 14503-14509
22. 22. Nelson JM, Slintak V, Denny WA, Smaill JB, Rewcastle GW, Showalter HDH, Bridges AJ, Zhou H, McNamara DJ, Dobrusin EM, Fry DW (1998) In vitro comparison of irreversible versus reversible inhibition for a series of substituted quinazolines and pyridopyrimidines that are potent and specific inhibitors of the epidermal growth factor receptor (EGFR) family of tyrosine kinases. In: Proceedings of the Annual Meeting of the Association of Cancer Research, vol 39. Cadmus Journal Services, Linthicum, p 316
23. 23. Ouyang X, Huang GC, Chantry A, Epstein RJ (1998) Adjacent carboxyterminal tyrosine phosphorylation events identify functionally distinct ErbB2 receptor subsets: implications for molecular diagnostics. Exp Cell Res 241: 467-475
24. 24. Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH (1977) Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther 1: 411-435
25. 25. Sunada H, Yu P, Peacock JS, Medelshon J (1990) Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J Cell Physiol 142: 284-292
26. 26. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212
27. 27. Vincent PW, Atkinson BE, Zhou H, Dykes D, Leopold WR, Patmore SJ, Roberts BJ, Bridges AJ, Elliott WL (1998) Characterization of the in vivo activity of a novel EGF receptor family kinase inhibitor, PD 0169414 (meeting abstract). In: Proceedings of the Annual Meeting of the Association of Cancer Research, vol 39. Cadmus Journal Services, Linthicum, p 560
28. 28. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, Woodburn JR (1996) Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 38: 67-73
29. 29. Workman P, Brunton VG, Robins DJ (1992) Tyrosine kinase inhibitors. Semin Cancer Biol 3: 369-381
30. 30. Yarden Y, Ullrich A (1988) Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443-478